Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

193
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
193

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: The STARD-AI reporting guideline for diagnostic accuracy studies using artificial intelligence.

Nature medicine·2026
Same author

Accelerating scientific discovery with Co-Scientist.

ArXiv·2026
Same author

From Chatbots to Co-Scientists: The Impact of Knowledge-Generating AI (AI 4.0) on Healthcare and Research.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Polymerization Kinetics-Mediated Topological Entanglement Enables High-Contrast 3D Self-Morphing in Hydrogels.

Angewandte Chemie (International ed. in English)·2026
Same author

Cost-effectiveness thresholds for initiating osteoporosis treatment in postmenopausal women in China: a microsimulation analysis based on real-world data.

Archives of osteoporosis·2026
Same author

Towards Conversational AI for Disease Management.

Nature·2026

Related Experiment Video

Updated: Jan 6, 2026

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.6K

AI-Assisted Drug Re-Purposing for Human Liver Fibrosis.

Yuan Guan1, Lu Cui2, Jakkapong Inchai1,3

  • 1Department of Anesthesiology, Pain and Perioperative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|September 14, 2025
PubMed
Summary

This study repurposed drugs for liver fibrosis using an AI co-scientist and human hepatic organoids. Two AI-recommended drugs, including Vorinostat, showed significant anti-fibrotic effects and promoted liver regeneration.

Keywords:
artificial Intelligencehepatic Organoidsliver fibrosis

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.2K
A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
08:40

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

6.7K

Related Experiment Videos

Last Updated: Jan 6, 2026

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.6K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.2K
A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
08:40

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

6.7K

Area of Science:

  • Hepatology
  • Artificial Intelligence
  • Drug Discovery

Background:

  • Liver fibrosis lacks effective treatments due to inadequate research models.
  • Developing novel therapeutic strategies for liver fibrosis is critical.

Purpose of the Study:

  • To repurpose existing drugs for liver fibrosis treatment using an AI co-scientist.
  • To experimentally validate drug efficacy and toxicity in human hepatic organoids.

Main Methods:

  • Utilized a multi-agent AI system (AI co-scientist) for drug repurposing.
  • Assessed 25 drugs for anti-fibrotic efficacy and toxicity in human hepatic organoids (microHOs).
  • Focused on drugs targeting epigenomic modifiers.

Main Results:

  • Identified three known and two AI-recommended drugs with significant anti-fibrotic activity.
  • Observed that these drugs promoted liver regeneration and reduced myofibroblast generation.
  • Demonstrated that AI-recommended drug Vorinostat reduced TGFβ-induced chromatin changes by 91%.

Conclusions:

  • AI co-scientist and microHO platform identified novel liver fibrosis treatments.
  • Epigenomic modifications are crucial in liver fibrosis pathogenesis.
  • New drug candidates promote both liver fibrosis treatment and regeneration.